- Home
- BMO vs BDX Comparison
BMO vs BDX Comparison
Compare BMO & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMO | BDX |
|---|---|---|
| Founded | 1817 | 1897 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.6B | 51.5B |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | BMO | BDX |
|---|---|---|
| Price | $137.78 | $155.00 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $163.00 | ★ $188.73 |
| AVG Volume (30 Days) | 705.0K | ★ 2.1M |
| Earning Date | 05-27-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.45% | 2.70% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.34 |
| Revenue | N/A | ★ $21,840,000,000.00 |
| Revenue This Year | $19.28 | N/A |
| Revenue Next Year | $4.45 | $2.22 |
| P/E Ratio | ★ $17.46 | $115.84 |
| Revenue Growth | N/A | ★ 8.24 |
| 52 Week Low | $85.52 | $152.99 |
| 52 Week High | $149.01 | $213.08 |
Technical Indicators
Market Signals| Indicator | BMO | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 50.89 | 33.82 |
| Support Level | $135.30 | $153.75 |
| Resistance Level | $147.68 | $160.19 |
| Average True Range (ATR) | 2.62 | 3.28 |
| MACD | 0.32 | 0.98 |
| Stochastic Oscillator | 69.38 | 33.24 |
Price Performance
Historical ComparisonAbout BMO Bank Of Montreal
Bank of Montreal is a diversified financial-services provider based in North America with over CAD 1.4 trillion in assets. BMO operates four business segments: Canadian personal and commercial banking, US personal and commercial banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the US.
About BDX Becton Dickinson and Company
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. On a 2025 sales basis, following the spinoff, BD Medical Essentials represented 34% of revenue, the Interventional segment 28%, Connected Care 25%, and Biopharma 13%. International revenue accounts for 43% of the company's business.